CA2847514A1 - Amino-substituted imidazopyridazines - Google Patents

Amino-substituted imidazopyridazines Download PDF

Info

Publication number
CA2847514A1
CA2847514A1 CA2847514A CA2847514A CA2847514A1 CA 2847514 A1 CA2847514 A1 CA 2847514A1 CA 2847514 A CA2847514 A CA 2847514A CA 2847514 A CA2847514 A CA 2847514A CA 2847514 A1 CA2847514 A1 CA 2847514A1
Authority
CA
Canada
Prior art keywords
alkyl
benzofuran
pyridazin
imidazo
oxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2847514A
Other languages
English (en)
French (fr)
Inventor
Knut Eis
Florian Puhler
Ludwig Zorn
Arne Scholz
Philip Lienau
Mark Jean Gnoth
Ulf Bomer
Judith Gunther
Marion Hitchcock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47831558&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2847514(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Intellectual Property GmbH filed Critical Bayer Intellectual Property GmbH
Publication of CA2847514A1 publication Critical patent/CA2847514A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)
  • Fats And Perfumes (AREA)
CA2847514A 2011-09-06 2012-09-05 Amino-substituted imidazopyridazines Abandoned CA2847514A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP11180129.6 2011-09-06
EP11180129 2011-09-06
EP11182440 2011-09-23
EP11182440.5 2011-09-23
EP12179902 2012-08-09
EP12179902.7 2012-08-09
PCT/EP2012/067264 WO2013034570A1 (en) 2011-09-06 2012-09-05 Amino-substituted imidazopyridazines

Publications (1)

Publication Number Publication Date
CA2847514A1 true CA2847514A1 (en) 2013-03-14

Family

ID=47831558

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2847514A Abandoned CA2847514A1 (en) 2011-09-06 2012-09-05 Amino-substituted imidazopyridazines

Country Status (36)

Country Link
US (1) US9499547B2 (OSRAM)
EP (1) EP2758401B1 (OSRAM)
JP (1) JP6174583B2 (OSRAM)
KR (1) KR20140059268A (OSRAM)
CN (1) CN103958515B (OSRAM)
AP (1) AP2014007496A0 (OSRAM)
AU (1) AU2012306422B2 (OSRAM)
BR (1) BR112014004687A2 (OSRAM)
CA (1) CA2847514A1 (OSRAM)
CL (1) CL2014000543A1 (OSRAM)
CO (1) CO6900146A2 (OSRAM)
CR (1) CR20140113A (OSRAM)
CY (1) CY1119433T1 (OSRAM)
DK (1) DK2758401T3 (OSRAM)
DO (1) DOP2014000051A (OSRAM)
EA (1) EA025688B1 (OSRAM)
EC (1) ECSP14013231A (OSRAM)
ES (1) ES2638319T3 (OSRAM)
GT (1) GT201400043A (OSRAM)
HR (1) HRP20171248T1 (OSRAM)
IL (1) IL231351A (OSRAM)
LT (1) LT2758401T (OSRAM)
MA (1) MA35422B1 (OSRAM)
ME (1) ME02951B (OSRAM)
MX (1) MX348064B (OSRAM)
MY (1) MY168413A (OSRAM)
PE (1) PE20141593A1 (OSRAM)
PH (1) PH12014500501A1 (OSRAM)
PL (1) PL2758401T3 (OSRAM)
PT (1) PT2758401T (OSRAM)
RS (1) RS56179B1 (OSRAM)
SG (1) SG11201400219PA (OSRAM)
SI (1) SI2758401T1 (OSRAM)
UA (1) UA117092C2 (OSRAM)
WO (1) WO2013034570A1 (OSRAM)
ZA (1) ZA201402498B (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103717604B (zh) 2011-06-01 2016-06-01 拜耳知识产权有限责任公司 取代的氨基咪唑并哒嗪
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
JP6174586B2 (ja) * 2011-09-23 2017-08-02 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 置換イミダゾピリダジン
EP2804864B1 (en) 2011-12-12 2017-09-06 Bayer Intellectual Property GmbH Amino-substituted imidazopyridazines
ES2663609T3 (es) * 2012-03-29 2018-04-16 Bayer Intellectual Property Gmbh Imidazopiridazinas amino-sustituidas
JP6173430B2 (ja) 2012-04-04 2017-08-02 バイエル・ファルマ・アクティエンゲゼルシャフト アミノ置換イミダゾピリダジン
CN104797585B (zh) 2012-11-19 2017-08-15 拜耳医药股份公司 氨基咪唑并哒嗪
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
NZ749911A (en) 2013-01-15 2020-02-28 Incyte Holdings Corp Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
JP2016506943A (ja) 2013-01-30 2016-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト Mknk−1キナーゼ阻害剤としてのアミドイミダゾピリダジン類
WO2014128093A1 (en) * 2013-02-20 2014-08-28 Bayer Pharma Aktiengesellschaft Substituted-imidazo[1,2-b]pyridazines as mknk1 inhibitors
EP3036238A1 (en) 2013-08-23 2016-06-29 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US10214545B2 (en) 2014-01-09 2019-02-26 Bayer Pharma Aktiengesellschaft Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
JP2018500344A (ja) * 2014-12-23 2018-01-11 バイエル・ファルマ・アクティエンゲゼルシャフト 6−ヒドロキシベンゾフラニル置換および6−アルコキシベンゾフラニル置換イミダゾピリダジン
CA2982984C (en) 2015-04-20 2023-10-17 Effector Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Pim激酶抑制劑之鹽
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
US20170191136A1 (en) * 2015-12-31 2017-07-06 Effector Therapeutics, Inc. Mnk biomarkers and uses thereof
WO2017157418A1 (en) 2016-03-15 2017-09-21 Bayer Pharma Aktiengesellschaft Combination of mknk1-inhibitors
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4408047A (en) 1980-03-28 1983-10-04 Merck & Co., Inc. Imidazodiazines
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
FR2619818B1 (fr) 1987-09-01 1990-01-12 Sanofi Sa Imidazo (1,2-b) pyridazines, procede pour leur preparation et compositions pharmaceutiques les contenant
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
EP1426050A4 (en) 2001-08-23 2005-05-25 Takeda Pharmaceutical JNK INHIBITORS
US20100216798A1 (en) 2005-07-29 2010-08-26 Astellas Pharma Inc Fused heterocycles as lck inhibitors
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US7750000B2 (en) * 2005-09-02 2010-07-06 Bayer Schering Pharma Ag Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
WO2007033080A2 (en) 2005-09-12 2007-03-22 Emory University Alzheimer's disease imaging agents
DE102006029447A1 (de) * 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel
JP2009541268A (ja) 2006-06-22 2009-11-26 ビオヴィトルム・アクチボラゲット(プブリクト) Mnkキナーゼ阻害剤としてのピリジンおよびピラジン誘導体
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
EP1900739A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Diazolodiazine derivatives as kinase inhibitors
CA2663091A1 (en) * 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Modulators of interleukin-1 receptor-associated kinase
CN101522682A (zh) 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
CN101600718B (zh) 2006-11-06 2013-07-03 特雷罗药物股份有限公司 咪唑并[1,2-b]哒嗪和吡唑并[1,5-a]嘧啶衍生物及其作为蛋白激酶抑制剂的用途
WO2008072682A1 (ja) 2006-12-15 2008-06-19 Daiichi Sankyo Company, Limited イミダゾ[1,2-b]ピリダジン誘導体
AR064420A1 (es) 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
US20110046127A1 (en) 2007-11-08 2011-02-24 Paolo Pevarello Imidazopyridazines for Use as Protein Kinase Inhibitors
BRPI0822240A2 (pt) 2007-12-21 2015-06-30 Wyeth Llc Composto imidazo [1,2-b] piridazina como moduladores de receptores x hepáticos
EP2710004A1 (en) * 2011-05-17 2014-03-26 Bayer Intellectual Property GmbH Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
CN103717604B (zh) 2011-06-01 2016-06-01 拜耳知识产权有限责任公司 取代的氨基咪唑并哒嗪
WO2012175591A1 (en) 2011-06-22 2012-12-27 Bayer Intellectual Property Gmbh Heterocyclyl aminoimidazopyridazines
AR087701A1 (es) 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
JO3192B1 (ar) 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
US9353081B2 (en) 2011-09-23 2016-05-31 Hoffmann-La Roche Inc. Bicyclic dihydroquinoline-2-one derivatives
JP6174586B2 (ja) 2011-09-23 2017-08-02 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 置換イミダゾピリダジン
EP2804864B1 (en) 2011-12-12 2017-09-06 Bayer Intellectual Property GmbH Amino-substituted imidazopyridazines
ES2663609T3 (es) 2012-03-29 2018-04-16 Bayer Intellectual Property Gmbh Imidazopiridazinas amino-sustituidas
JP6173430B2 (ja) 2012-04-04 2017-08-02 バイエル・ファルマ・アクティエンゲゼルシャフト アミノ置換イミダゾピリダジン
CN104797585B (zh) 2012-11-19 2017-08-15 拜耳医药股份公司 氨基咪唑并哒嗪
JP2016506943A (ja) 2013-01-30 2016-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト Mknk−1キナーゼ阻害剤としてのアミドイミダゾピリダジン類
WO2014128093A1 (en) 2013-02-20 2014-08-28 Bayer Pharma Aktiengesellschaft Substituted-imidazo[1,2-b]pyridazines as mknk1 inhibitors
US10214545B2 (en) 2014-01-09 2019-02-26 Bayer Pharma Aktiengesellschaft Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders

Also Published As

Publication number Publication date
HRP20171248T1 (hr) 2017-10-20
GT201400043A (es) 2015-04-06
KR20140059268A (ko) 2014-05-15
ZA201402498B (en) 2017-09-27
ECSP14013231A (es) 2014-04-30
EP2758401A1 (en) 2014-07-30
HK1199732A1 (en) 2015-07-17
AU2012306422B2 (en) 2017-10-26
UA117092C2 (uk) 2018-06-25
JP2014525469A (ja) 2014-09-29
EP2758401B1 (en) 2017-05-31
EA201400311A1 (ru) 2014-09-30
SG11201400219PA (en) 2014-03-28
ME02951B (me) 2018-07-20
PT2758401T (pt) 2017-08-30
CO6900146A2 (es) 2014-03-20
AP2014007496A0 (en) 2014-03-31
EA025688B1 (ru) 2017-01-30
RS56179B1 (sr) 2017-11-30
NZ622129A (en) 2016-06-24
BR112014004687A2 (pt) 2017-03-28
AU2012306422A1 (en) 2014-03-27
CN103958515B (zh) 2016-11-09
PL2758401T3 (pl) 2017-11-30
ES2638319T3 (es) 2017-10-19
MX2014002697A (es) 2014-04-25
CY1119433T1 (el) 2018-03-07
US9499547B2 (en) 2016-11-22
CR20140113A (es) 2014-05-02
MY168413A (en) 2018-11-09
CN103958515A (zh) 2014-07-30
US20140296231A1 (en) 2014-10-02
SI2758401T1 (sl) 2017-10-30
PE20141593A1 (es) 2014-11-12
DOP2014000051A (es) 2014-06-01
MA35422B1 (fr) 2014-09-01
JP6174583B2 (ja) 2017-08-02
AP3853A (OSRAM) 2016-09-30
DK2758401T3 (en) 2017-09-11
WO2013034570A1 (en) 2013-03-14
LT2758401T (lt) 2017-08-25
PH12014500501A1 (en) 2021-06-02
IL231351A0 (en) 2014-04-30
CL2014000543A1 (es) 2014-09-26
IL231351A (en) 2017-01-31
MX348064B (es) 2017-05-26

Similar Documents

Publication Publication Date Title
AU2012306422B2 (en) Amino-substituted imidazopyridazines
EP2804864B1 (en) Amino-substituted imidazopyridazines
EP2714692B1 (en) Substituted aminoimidazopyridazines
EP2723748B1 (en) Heterocyclyl aminoimidazopyridazines
EP2920176B1 (en) Aminoimidazopyridazines as mknk1 kinase inhibitors
CA2849345A1 (en) Substituted imidazopyridazines
CA2836203A1 (en) Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
CA2868673A1 (en) Amino-substituted imidazopyridazines
CA2899352A1 (en) Amidoimidazopyridazines as mknk-1 kinase inhibitors
CA2869212A1 (en) Amino-substituted imidazopyridazines
CA2936024A1 (en) Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders
CA2971536A1 (en) 6-hydroxybenzofuranyl- and 6-alkoxybenzofuranyl-substituted imidazopyridazines
NZ622129B2 (en) Amino-substituted imidazopyridazines

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170831

FZDE Discontinued

Effective date: 20190905